
The 3-year follow-up of 100 patients from a clinical trial found MSC-treated patients had better general health scores (67.0 vs. 50.0) and lower reinfection rates (53.06% vs. 67.86%). No major differences in lung function, Long COVID symptoms, or new complications were observed. These findings confirm the long-term safety and potential benefits of MSC therapy.
Like
Save
Share